Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Evolving into a phase II company
Press releases
-
The subscription period in AlzeCure Pharma AB’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank
December 6, 2022
-
AlzeCure Pharma AB publishes prospectus and invites to investor presentations
December 1, 2022
-
New data on Alzstatin for preventive treatment against Alzheimer’s presented at Alzheimer’s conference CTAD
December 1, 2022